Biotech News

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

Immix Biopharma (IMMX)Immix BiopharmaFinancing

- Financing includes leading U.S. biotechnology institutional investors and mutual funds -

LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "we" or "us" or "IMMX"), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its...

Related news

Immix Biopharma

Cell-Therapy Developer Immix Biopharma is a clinical-stage biotechnology company developing autologous CAR T-cell therapies for hematologic diseases. Its lead program is designed around a differentiated BCMA-targeted construct. NXC-201 Lead Program NXC-201 is a BCMA-directed CAR T-cell therapy with a proprietary binder, CD8 hinge, and...

Recent company news

Stock data

Close
7.04 USD
Market cap
595.5M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States